PI
CYTK icon

Putnam Investments’s Cytokinetics CYTK Stock Holding History

Putnam Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$30.5M Buy
365,335
+147,486
+68% +$5.34M 0.04% 175
2023
Q3 		$6.42M Buy
217,849
+7,519
+4% +$250K 0.01% 393
2023
Q2 		$6.86M Buy
210,330
+10,662
+5% +$394K 0.01% 390
2023
Q1 		$7.03M Sell
199,668
-129
-0.1% -$5.26K 0.01% 383
2022
Q4 		$9.15M Buy
199,797
+694
+0.3% +$29.9K 0.02% 304
2022
Q3 		$9.65M Sell
199,103
-991
-0.5% -$47.7K 0.02% 296
2022
Q2 		$7.86M Buy
200,094
+1,014
+0.5% +$40.8K 0.01% 341
2022
Q1 		$7.33M Buy
199,080
+4,069
+2% +$145K 0.01% 413
2021
Q4 		$8.89M Buy
195,011
+63,357
+48% +$2.44M 0.01% 398
2021
Q3 		$4.71M Buy
+131,654
New +$3.88M 0.01% 538

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Putnam Investments's CYTK Position: Q4 2023 in Review

Putnam Investments increased its Cytokinetics (CYTK) stake by 68% in Q4 2023, buying an estimated $5.34M and bringing the position to 365,335 shares worth $30.5M. The position accounts for 0.04% of the portfolio, ranked #175.

Putnam Investments first reported a position in CYTK in Q3 2021 and has held it in 10 quarters since. 347 funds tracked by Wall St. Rank hold CYTK as of Q4 2023.

  • Putnam Investments held 365,335 shares of Cytokinetics worth $30.5M as of Q4 2023.
  • Putnam Investments bought 147,486 Cytokinetics shares in Q4 2023, an estimated $5.34M.
  • Cytokinetics made up 0.04% of Putnam Investments's portfolio in Q4 2023, its #175 holding.
  • Putnam Investments first reported a position in Cytokinetics in Q3 2021 and has held it in 10 quarters since.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.